Annual General Meeting of Active Biotech AB

        Print
| Source: Active Biotech AB
The Annual General Meeting of Active Biotech was held on May 15, 2013.

In accordance with the Board of Directors' proposal, it was resolved that no
dividend would be paid.

In  accordance with  the Election  Committee's proposal,  the Board members Mats
Arnhög,  Peter Hofvenstam, Magnhild  Sandberg, Peter Sjöstrand  and Peter Thelin
were  re-elected. Rolf Kiessling was elected as  a new Board member. The Meeting
also  resolved to re-elect Mats Arnhög as Chairman of the Board. KPMG AB was re-
elected as auditors.

Furthermore, in accordance with the Election Committee's proposal, the Meeting
resolved that the Election Committee shall be composed of representatives for
the three largest owners, as per the end of September, 2013, as well as the
Chairman of the Board.

The Meeting approved the Board's proposal concerning guidelines for remuneration
to the President and other senior executives. The guidelines essentially conform
to the principles applied to date.

In accordance with the Board's proposal, the Meeting resolved to authorize the
Board, for a period that does not extend past the date of the next Annual
General Meeting, to resolve on the issue of not more than seven million new
shares and/or convertibles with the corresponding dilution effect, with or
without pre-emptive rights for the company's shareholders.


Lund, May 16, 2013

Active Biotech AB (publ)

Tomas Leanderson
President and CEO



Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In addition, laquinimod is in Phase II development for Crohn's and Lupus. The
company also has one additional project in clinical development, the orally
administered compound paquinimod (57-57) for systemic sclerosis. Please visit
www.activebiotech.com for more information.

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with the Swedish  Securities Market Act. This information
was provided to the media for publication 08:30 a.m. CET on May 16, 2013.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00


[HUG#1701975]